The rapid advances in bio-science and bio-technology have resulted in a wealth of dynamic new industries and promise great advances in medical therapies and related benefits. However, the underlying science that forms the basis of developments in genomics, gene therapy and related areas also poses new problems for both the regulatory and traditional intellectual property rights systems. The complex balance between rewarding the inventor and investor, while at the same time not shutting out fair competition, has been highlighted in a series of recent cases.
Bio-Science Law Review is a peer-reviewed journal and reports and analyses these developments and acts as a forum for discussion of the legal protection and approval of these new technologies. Recent coverage has included critical analysis of the SPC decisions, pay for delay and other competition law issues.
Regular coverage on developments in patent law and practice, joint ventures
and other forms of collaboration, the legal issues of raising finance for bio-science
industries, competition law issues, trade mark developments and reports on the
activities of regulatory agencies such as the EMA and FDA.